EMA Authorised: Onbrez Breezhaler (indacaterol maleate) — Novartis Europharm Limited

View source ↗

Summary

EU marketing authorization granted for Onbrez Breezhaler (indacaterol maleate) for chronic obstructive pulmonary disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Onbrez Breezhaler (indacaterol maleate)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: Novartis Europharm Limited. Decision date: 18/11/2025